We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The World Health Organization (WHO) has stated that increasing numbers of people around the world are vulnerable to polio because they have not been previously exposed to the disease.
The Department of Health and Human Services (HHS) has announced it will purchase 10,000 therapeutic courses of anthrax immune globulin (AIG) from Cangene of Winnipeg, Manitoba, for approximately $143 million.
Sanofi Pasteur MSD, the joint venture of Sanofi Pasteur and Merck, announced that Gardasil (quadrivalent human papillomavirus recombinant vaccine), has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP).
The drug control departments of India's northeastern states will soon begin to enforce more strict good manufacturing practices (GMP) in pharmaceutical plants.
Sirion Therapeutics, Inc., an ophthalmic focused pharmaceutical company, has reached an exclusive licensing agreement with Laboratories Sophia S.A.de C.V. of Mexico for the US rights to develop and market a unique topical solution with the active ingredient cyclosporine A for ophthalmic use.
PLIVA, headquartered at Croatia, has finalized an agreement with Mayne Pharma of Australia, for the continued development of biosimilar granulocyte-colony stimulating factor (G-CSF) for the European, South East Asian, Middle Eastern and Asia Pacific markets.
Schering-Plough Corporation announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has granted a positive opinion recommending approval of SUBOXONE (buprenorphine hydrochloride/naloxone hydrochloride) Sublingual Tablets for the substitution treatment of opioid dependence, within a framework of medical, social and psychological treatment.
Albany Molecular Research, Inc. (AMRI), a global drug discovery company, has announced, that a multi-year drug substance manufacturing agreement with New River Pharmaceuticals Inc., Financial terms were not disclosed. Under the agreement, AMRI will manufacture the active pharmaceutical ingredient, in New River's compound, NRP104, a new treatment for attention deficit hyperactivity disorder (ADHD) that is currently under review with the US Food and Drug Administration.
Italy-based pharmaceutical firm Recordati has received approval for its antihypertensive Zanitek, a fixed combination of lercanidipine and enalapril, from the German medicines agency, BfArM.